---
document_datetime: 2025-11-23 08:01:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/trevaclyn.html
document_name: trevaclyn.html
version: success
processing_time: 0.117685
conversion_datetime: 2025-12-27 17:57:11.870683
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Trevaclyn

[RSS](/en/individual-human-medicine.xml/65565)

##### Withdrawn

This medicine's authorisation has been withdrawn

laropiprant / nicotinic acid

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Trevaclyn](#news-on)
- [More information on Trevaclyn](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On the 3 July 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal products Trevaclyn (nicotinic acid/laropiprant), which had been approved for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDLcholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and nonfamilial).

The marketing authorisation holder (MAH) responsible for Trevaclyn was Merck Sharp &amp; Dohme Ltd. The European Commission was notified by a letter dated 20 March 2013 of the MAH's decision to voluntarily withdraw the marketing authorisations. This followed the CHMP' recommendation to suspend the marketing authorisations of these products on 17 January 2013. None of the products are currently marketed in any EU country.

On 10 April 2013 the European Commission issued a decision to withdraw the marketing authorisations for Trevaclyn.

Pursuant to this decision the European Public Assessment Reports for Trevaclyn is updated to reflect the fact that the marketing authorisations are no longer valid.

Trevaclyn : EPAR - Summary for the public

English (EN) (498.31 KB - PDF)

**First published:** 10/07/2008

**Last updated:** 10/07/2008

[View](/en/documents/overview/trevaclyn-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-735)

български (BG) (236.98 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/bg/documents/overview/trevaclyn-epar-summary-public_bg.pdf)

español (ES) (44.93 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/es/documents/overview/trevaclyn-epar-summary-public_es.pdf)

čeština (CS) (164.48 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/cs/documents/overview/trevaclyn-epar-summary-public_cs.pdf)

dansk (DA) (44.75 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/da/documents/overview/trevaclyn-epar-summary-public_da.pdf)

Deutsch (DE) (45.84 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/de/documents/overview/trevaclyn-epar-summary-public_de.pdf)

eesti keel (ET) (42.99 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/et/documents/overview/trevaclyn-epar-summary-public_et.pdf)

ελληνικά (EL) (170.72 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/el/documents/overview/trevaclyn-epar-summary-public_el.pdf)

français (FR) (45.45 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/fr/documents/overview/trevaclyn-epar-summary-public_fr.pdf)

italiano (IT) (44.93 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/it/documents/overview/trevaclyn-epar-summary-public_it.pdf)

latviešu valoda (LV) (165.1 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/lv/documents/overview/trevaclyn-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (157.86 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/lt/documents/overview/trevaclyn-epar-summary-public_lt.pdf)

magyar (HU) (154.69 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/hu/documents/overview/trevaclyn-epar-summary-public_hu.pdf)

Malti (MT) (167.26 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/mt/documents/overview/trevaclyn-epar-summary-public_mt.pdf)

Nederlands (NL) (45.31 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/nl/documents/overview/trevaclyn-epar-summary-public_nl.pdf)

polski (PL) (171.6 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/pl/documents/overview/trevaclyn-epar-summary-public_pl.pdf)

português (PT) (45.36 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/pt/documents/overview/trevaclyn-epar-summary-public_pt.pdf)

română (RO) (153.16 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/ro/documents/overview/trevaclyn-epar-summary-public_ro.pdf)

slovenčina (SK) (159.24 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/sk/documents/overview/trevaclyn-epar-summary-public_sk.pdf)

slovenščina (SL) (151.27 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/sl/documents/overview/trevaclyn-epar-summary-public_sl.pdf)

Suomi (FI) (43.3 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/fi/documents/overview/trevaclyn-epar-summary-public_fi.pdf)

svenska (SV) (43.51 KB - PDF)

**First published:**

10/07/2008

**Last updated:**

10/07/2008

[View](/sv/documents/overview/trevaclyn-epar-summary-public_sv.pdf)

## Product information

Trevaclyn : EPAR - Product Information

English (EN) (903.33 KB - PDF)

**First published:** 10/09/2009

**Last updated:** 31/05/2012

[View](/en/documents/product-information/trevaclyn-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-51)

български (BG) (386.63 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/bg/documents/product-information/trevaclyn-epar-product-information_bg.pdf)

español (ES) (250.34 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/es/documents/product-information/trevaclyn-epar-product-information_es.pdf)

čeština (CS) (318.59 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/cs/documents/product-information/trevaclyn-epar-product-information_cs.pdf)

dansk (DA) (271.25 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/da/documents/product-information/trevaclyn-epar-product-information_da.pdf)

Deutsch (DE) (256.18 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/de/documents/product-information/trevaclyn-epar-product-information_de.pdf)

eesti keel (ET) (242.75 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/et/documents/product-information/trevaclyn-epar-product-information_et.pdf)

ελληνικά (EL) (436.1 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/el/documents/product-information/trevaclyn-epar-product-information_el.pdf)

français (FR) (292.06 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/fr/documents/product-information/trevaclyn-epar-product-information_fr.pdf)

íslenska (IS) (275.88 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/is/documents/product-information/trevaclyn-epar-product-information_is.pdf)

italiano (IT) (232.55 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/it/documents/product-information/trevaclyn-epar-product-information_it.pdf)

latviešu valoda (LV) (373.52 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/lv/documents/product-information/trevaclyn-epar-product-information_lv.pdf)

lietuvių kalba (LT) (314.12 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/lt/documents/product-information/trevaclyn-epar-product-information_lt.pdf)

magyar (HU) (306.42 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/hu/documents/product-information/trevaclyn-epar-product-information_hu.pdf)

Malti (MT) (322.27 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/mt/documents/product-information/trevaclyn-epar-product-information_mt.pdf)

Nederlands (NL) (243.81 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/nl/documents/product-information/trevaclyn-epar-product-information_nl.pdf)

norsk (NO) (232.28 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/no/documents/product-information/trevaclyn-epar-product-information_no.pdf)

polski (PL) (357.36 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/pl/documents/product-information/trevaclyn-epar-product-information_pl.pdf)

português (PT) (236.12 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/pt/documents/product-information/trevaclyn-epar-product-information_pt.pdf)

română (RO) (341.21 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/ro/documents/product-information/trevaclyn-epar-product-information_ro.pdf)

slovenčina (SK) (354.65 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/sk/documents/product-information/trevaclyn-epar-product-information_sk.pdf)

slovenščina (SL) (282.93 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/sl/documents/product-information/trevaclyn-epar-product-information_sl.pdf)

Suomi (FI) (253.44 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/fi/documents/product-information/trevaclyn-epar-product-information_fi.pdf)

svenska (SV) (246 KB - PDF)

**First published:**

10/09/2009

**Last updated:**

31/05/2012

[View](/sv/documents/product-information/trevaclyn-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A20/0038 10/04/2013

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Trevaclyn : EPAR - All Authorised presentations

English (EN) (466.2 KB - PDF)

**First published:** 26/01/2009

**Last updated:** 26/01/2009

[View](/en/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-722)

български (BG) (126.28 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/bg/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_bg.pdf)

español (ES) (34.63 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/es/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_es.pdf)

čeština (CS) (122.38 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/cs/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (35.36 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/da/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.87 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/de/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.98 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/et/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (118.6 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/el/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_el.pdf)

français (FR) (30.79 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/fr/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (33.85 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/it/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (121.11 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/lv/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (122.68 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/lt/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (122.65 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/hu/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (119.84 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/mt/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (34.11 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/nl/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_nl.pdf)

polski (PL) (74.77 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/pl/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.65 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/pt/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_pt.pdf)

română (RO) (119.72 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/ro/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (118.39 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/sk/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.32 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/sl/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (34.27 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/fi/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (34.61 KB - PDF)

**First published:**

26/01/2009

**Last updated:**

26/01/2009

[View](/sv/documents/all-authorised-presentations/trevaclyn-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Trevaclyn Active substance

- laropiprant
- nicotinic acid

International non-proprietary name (INN) or common name

- laropiprant
- nicotinic acid

Therapeutic area (MeSH) Dyslipidemias Anatomical therapeutic chemical (ATC) code C10AD52

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).

Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.

## Authorisation details

EMA product number EMEA/H/C/000897 Marketing authorisation holder

Merck Sharp  Dohme Ltd

Hertford Road

Marketing authorisation issued 03/07/2008 Withdrawal of marketing authorisation 10/04/2013 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Trevaclyn : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (654.34 KB - PDF)

**First published:** 10/09/2009

**Last updated:** 22/03/2013

[View](/en/documents/procedural-steps-after/trevaclyn-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Trevaclyn : EPAR - Scientific Conclusion

English (EN) (521.17 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_en.pdf)

[Other languages (21)](#file-language-dropdown-205)

български (BG) (683.63 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/bg/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_bg.pdf)

español (ES) (570.47 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/es/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_es.pdf)

čeština (CS) (631.16 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/cs/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_cs.pdf)

dansk (DA) (526.48 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/da/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (530.84 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/de/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (527.29 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/et/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (682.84 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/el/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_el.pdf)

français (FR) (526.11 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/fr/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_fr.pdf)

italiano (IT) (523.69 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/it/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (638.4 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/lv/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (567.28 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/lt/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_lt.pdf)

magyar (HU) (619.56 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/hu/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_hu.pdf)

Malti (MT) (638.74 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/mt/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (524.86 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/nl/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_nl.pdf)

polski (PL) (633.08 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/pl/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_pl.pdf)

português (PT) (526.29 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/pt/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_pt.pdf)

română (RO) (563 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/ro/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (626.93 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/sk/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (625.17 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/sl/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (524.96 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/fi/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_fi.pdf)

svenska (SV) (526.11 KB - PDF)

**First published:**

22/03/2013

**Last updated:**

22/03/2013

[View](/sv/documents/scientific-conclusion/trevaclyn-epar-scientific-conclusion_sv.pdf)

Trevaclyn-H-C-897-A20-38 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/45910/2013

English (EN) (660.83 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/variation-report/trevaclyn-h-c-897-a20-38-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Trevaclyn : EPAR - Public assessment report

English (EN) (1.4 MB - PDF)

**First published:** 10/07/2008

**Last updated:** 10/07/2008

[View](/en/documents/assessment-report/trevaclyn-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Trevaclyn

Reference Number: EMEA/CHMP/196882/2008

English (EN) (34.38 KB - PDF)

**First published:** 24/04/2008

**Last updated:** 24/04/2008

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-trevaclyn_en.pdf)

#### News on Trevaclyn

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-january-2013) 18/01/2013

[European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn](/en/news/european-medicines-agency-confirms-recommendation-suspend-tredaptive-pelzont-trevaclyn) 18/01/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 January 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-january-2013) 11/01/2013

[European Medicines Agency starts review of Tredaptive, Pelzont and Trevaclyn](/en/news/european-medicines-agency-starts-review-tredaptive-pelzont-trevaclyn) 21/12/2012

#### More information on Trevaclyn

- [Tredaptive, Pelzont and Trevaclyn - referral](/en/medicines/human/referrals/tredaptive-pelzont-trevaclyn)

**This page was last updated on** 16/05/2013

## Share this page

[Back to top](#main-content)